Evommune (EVMN) Change in Accured Expenses (2024 - 2026)

Evommune (EVMN) has 3 years of Change in Accured Expenses data on file, last reported at -$4.8 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 128.97% year-over-year to -$4.8 million in Q1 2026; TTM through Mar 2026 was -$2.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.8 million, up 4.22% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.8 million, down from $4.3 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for EVMN reached as high as $4.3 million in Q4 2025 and fell as low as -$4.8 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$689500.0 across 3 years, with a median of -$1.1 million in 2024.
• Across the five-year window, Change in Accured Expenses surged 3169.29% in 2025 and sank 128.97% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at -$140000.0 in 2024, then jumped by 3169.29% to $4.3 million in 2025, then slumped by 212.01% to -$4.8 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$4.8 million in Q1 2026, $4.3 million in Q4 2025, and -$2.1 million in Q1 2025.